ArticleRespiratory research2015
Health-related quality of life is inversely correlated with C-reactive protein and age in Mycobacterium avium complex lung disease: a cross-sectional analysis of 235 patients.
Article in Respiratory research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Intermittent versus Daily Therapy for NoncavitaryAnnals of the American Thoracic Society · 2025Trial
- Clinical characteristics of pulmonary non-tuberculous mycobacterial disease withBMJ open respiratory research · 2026Article
- [Factors influencing health-related quality of life among patients with non-tuberculous mycobacterial pulmonary disease in South Korea: a cross-sectional survey study].Journal of Korean biological nursing science · 2025Article
- A two-sample mendelian randomization study of non-tuberculous mycobacteria infection and lung cancer.Journal of thoracic disease · 2024Article
- Variables associated with antibiotic treatment tolerance in patients with Mycobacterium avium complex pulmonary disease.Respiratory research · 2024Review
- Longitudinal significance of six-minute walk test in patients with nontuberculous mycobacterial pulmonary disease: an observational study.BMC pulmonary medicine · 2023Observational
- Treatment of Nontuberculous Mycobacterial Lung Disease Is Complex; Thus, Shared Decision Making Is Critical.Annals of the American Thoracic Society · 2022Article
- Comorbidities of nontuberculous mycobacteria infection in Korean adults: results from the National Health Insurance Service-National Sample Cohort (NHIS-NSC) database.BMC pulmonary medicine · 2022Article
- Osteoporosis in nontuberculous mycobacterial pulmonary disease: a cross-sectional study.BMC pulmonary medicine · 2022Article
- Development of Rheumatoid Arthritis in CavitaryInfection and drug resistance · 2022Article
- Early-Phase Adverse Effects and Management of Liposomal Amikacin Inhalation for RefractoryInfection and drug resistance · 2022Article
- Psychometric Validation of the EQ-5D-3L in Patients with Nontuberculous Mycobacterial (NTM) Lung Disease Caused byPatient related outcome measures · 2021Article
- Comorbidities associated with nontuberculous mycobacterial disease in Japanese adults: a claims-data analysis.BMC pulmonary medicine · 2020Article
- The impact of adjuvant surgical treatment of nontuberculous mycobacterial pulmonary disease on prognosis and outcome.Respiratory research · 2020Article
- Prospective examination of synthetic 5-methoxy-N,N-dimethyltryptamine inhalation: effects on salivary IL-6, cortisol levels, affect, and non-judgment.Psychopharmacology · 2020Observational
- Sitafloxacin-Containing Regimen for the Treatment of RefractoryOpen forum infectious diseases · 2019Article
- Treatment ofTuberculosis and respiratory diseases · 2019Review
- Association between six-minute walk test parameters and the health-related quality of life in patients with pulmonary Mycobacterium avium complex disease.BMC pulmonary medicine · 2018Article
- Natural history of Mycobacterium fortuitum pulmonary infection presenting with migratory infiltrates: a case report with microbiological analysis.BMC infectious diseases · 2018Article
- Optimization and Lead Selection of Benzothiazole Amide Analogs Toward a Novel Antimycobacterial Agent.Frontiers in microbiology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMycobacterium avium complex (MAC) lung diseases generally cause chronic disease in immunocompetent hosts. Although a few studies have examined health-related quality of life (HRQL) in patients with MAC lung disease, there have been no large studies. This study aimed to evaluate HRQL and its correlation with clinical outcomes in MAC lung disease.
methodsA cross-sectional study was conducted at Keio University Hospital to investigate the factors associated with HRQL in pulmonary nontuberculous mycobacterial diseases. MAC lung diseases were diagnosed according to the 2007 ATS/IDSA guidelines for nontuberculous mycobacterial diseases. The 36-item short form health survey (SF-36) was administered to assess clinical outcomes. Clinical variables included treatment status, latest haematological data, and bacterial smear and culture results.
resultsThe SF-36 scores for the 235 patients (median age, 69 years; 45 men and 190 women) with MAC lung disease, except for the bodily pain and mental health subscale scores, were significantly lower than the Japanese population norms. In the multivariable analyses, current treatment for MAC and a positive sputum smear or culture within the past year were significantly associated with lower SF-36 scores. C-reactive protein (CRP) and age showed stronger inverse correlations with SF-36 scores.
conclusionsHRQL, especially the physical component, was impaired in patients with MAC lung diseases; this appears to be related with current treatment status, positive sputum smear or culture within the previous year, and particularly CRP and age. Further studies including qualitative assessments are needed to investigate the efficacy of CRP as a marker for progression or treatment response in MAC lung disease.
trial registrationClinical trial registered with UMIN ( UMIN000007964 ).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.